Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity

Journal of Infectious Diseases

Volumn 211, Issue 6, 2015, Pages 889-897

  Gierer, Stefanie ^a   Müller, Marcel A ^b   Heurich, Adeline ^a   Ritz, Daniel ^b   Springstein, Benjamin L ^a   Karsten, Christina B ^a,c   Schendzielorz, Alexander ^a   Gnirß, Kerstin ^a   Drosten, Christian ^b   Pöhlmann, Stefan ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

activation; MERS coronavirus; proprotein convertase; protease; spike; TMPRSS2; trypsin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; PROTEINASE; SERINE PROTEINASE; VIRUS RECEPTOR; VIRUS SPIKE PROTEIN; ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORONAVIRUS INFECTION; ENZYME INHIBITION; ENZYME SUBSTRATE; FATALITY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HOST CELL; HUMAN; HUMAN CELL; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN SUBUNIT; PROTEIN SYNTHESIS; TARGET CELL; VIRUS ENTRY; VIRUS INFECTIVITY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CORONAVIRUS; DRUG SCREENING; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CORONAVIRUS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROPROTEIN CONVERTASES; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS INTERNALIZATION;

EID: 84924359597     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu407     Document Type: Article

References (50)

1. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013; 11:836-48
2. Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res 2013; 100:286-95
3. Drexler JF, Corman VM, Drosten C. Ecology, evolution and classification of bat coronaviruses in the aftermath of sars. Antiviral Res 2014; 101:45-56
4. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503:535-8
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20
6. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013; 13:745-51
7. Guery B, Poissy J, elMansouf L, et al. Clinical features and viral diagnosis of two cases of infection withMiddle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381:2265-72
8. Mailles A, Blanckaert K, Chaud P, et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013; 18:pii:20502
9. WHO. Update 16: summary and literature update as of 11 June 2014. 2014. http://www.who.int/csr/disease/coronavirus-infections/archive- updates/en/Accessed 8 July 2014
10. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) - update. 2014. http://www.who.int/csr/don/2014-07-04-mers/en/Accessed 8 July 2014
11. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012; 4:1011-33
12. Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 2012; 4:557-80
13. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4
14. Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87:5502-11
15. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Res 2013; 100:605-14
16. Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 2013; 87:12552-61
17. Qian Z, Dominguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One 2013; 8:e76469
18. Yamada Y, Liu DX. Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells. J Virol 2009; 83:8744-58
19. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992; 360:358-61
20. Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992; 11:2407-14
21. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3:753-66
22. Pasquato A, Ramos da Palma J, Galan C, Seidah NG, Kunz S. Viral envelope glycoprotein processing by proprotein convertases. Antiviral Res 2013; 99:49-60
23. Simmons G, Reeves JD, Grogan CC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003; 305:115-23
24. Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85:4122-34
25. Hofmann H, Simmons G, Rennekamp AJ, et al. Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol 2006; 80:8639-52
26. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995; 206:935-44
27. Gao F, Li Y, Decker JM, et al. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 2003; 19:817-23
28. Kühl A, Hoffmann M, Muller MA, et al. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J Infect Dis 2011; 204(suppl 3):S840-9
29. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012; 17:pii:20285
30. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012; 17:pii:20334
31. Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012; 287:21992-2003
32. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95:5762-7
33. Lenz O, ter Meulen J, Klenk HD, Seidah NG, GartenW. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci USA 2001; 98:12701-5
34. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11:367-83
35. Wilson CH, Abbott CA. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol 2012; 41:919-32
36. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002; 76:406-10
37. Neumann G, Geisbert TW, Ebihara H, et al. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 2007; 81:2995-8
38. Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol 2013; 87:6150-60
39. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 2012; 86:6537-45
40. Shirato K, Matsuyama S, Ujike M, Taguchi F. Role of proteases in the release of porcine epidemic diarrhea virus from infected cells. J Virol 2011; 85:7872-80
41. Kim TS, Heinlein C, Hackman RC, Nelson PS. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006; 26:965-75
42. Hofmann H, Li X, Zhang X, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol 2013; 87:4384-94
43. Alagaili AN, Briese T, Mishra N, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in saudi arabia. MBio 2014; 5:e00884-14
44. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013; 87: 11950-4
45. de Haan CA, Stadler K, Godeke GJ, Bosch BJ, Rottier PJ. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J Virol 2004; 78:6048-54
46. Frana MF, Behnke JN, Sturman LS, Holmes KV. Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion. J Virol 1985; 56:912-20
47. Cavanagh D, Davis PJ, Pappin DJ, Binns MM, Boursnell ME, Brown TD. Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor propolypeptide of IBV strains Beaudette and M41. Virus Res 1986; 4:133-43
48. Bergeron E, Vincent MJ, Wickham L, et al. Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. Biochem Biophys Res Commun 2005; 326:554-63
49. Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology 2006; 350:358-69
50. Simmons G, Bertram S, Glowacka I, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology 2011; 413:265-74